BGXX Stock ,Bright Green Returns vs. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| BGXX | -95% | |||
| S&P | -7.62% | +49.76% | +8.40% | +1% |
Bright Green Returns vs. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| BGXX | -95% | |||
| S&P | -7.62% | +49.76% | +8.40% | +1% |
Bright Green Company Info
Financial Health
General
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Revenue | $0.00M | – |
| Gross Profit | -$0.14M | -25.2% |
| Gross Margin | – | – |
| Market Cap | $172.60M | – |
| Market Cap / Employee | – | – |
| Employees | – | – |
| Net Income | -$5.78M | +1,125.3% |
| EBITDA | -$5.64M | +1,884.4% |
Assets
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $4.06M | – |
| Accounts Receivable | – | – |
| Inventory | 0 | – |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $2.03M | – |
| Short Term Debt | $0.00M | – |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | – | – |
| Return On Invested Capital | -26.4% | – |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | -$3.81M | – |
| Operating Free Cash Flow | -$0.80M | – |
Valuation
QUARTERLYANNUAL
| Q2 2022 | Q3 2022 | |
|---|---|---|
| Price to Earnings | – | – |
| Price to Book | 47.03 | 29.05 |
| Price to Sales | – | – |
| Price to Tangible Book Value | 47.04 | 29.06 |
| Price to Free Cash Flow TTM | – | – |
| Enterprise Value to EBITDA | -18.68 | -32.09 |
| Free Cash Flow Yield | – | – |
| Return on Equity | – | – |
| Total Debt | $2.00M | $2.03M |
Bright Green Stock
What was the cause?
BGXX Stock ,One of the most unusual stocks in the wildly different marijuana industry, Bright Green ( BGXX 19.81 percent), was quite the standout on Thursday. Contrary to the slow performance of the other marijuana stocks Bright Green’s share price soared an increase of more than 12 as a result of a slow-burn reaction to some positive news that the company had announced earlier during the week.
What’s the question?
What is it that makes Bright Green such a standout company is that it’s the only publically traded business authorized from the U.S. federal government to cultivate and sell (to licensed companies) marijuana and related products. It is technically illegal at the federal level, and this is the reason there aren’t many companies that are like Bright Green.
The morning of Tuesday, Bright Green announced -even though it is an unprofitable business that it had signed an agreement with U.K.’s Alterola Biotech to begin purchasing Alterola Biotech, a British marijuana-focused cannabis pharmaceutical business.
The initial phase of this process will be Bright Green purchase 25% of Alterola’s outstanding common stock at $4 million. The company will then be granted an option for six months to purchase the remaining shares of Alterola for $6 million. This will be accompanied by 40 million dollars worth Bright Green stock. The two companies will create a strategic alliance.
In its press release announcing the agreement, Bright Green wrote that it as well as Alterola “believe a successful collaboration will create a strong pathway to secure, provide, and supply cannabis and derivative products to the pharmaceutical industry.”
